Li Willis, Li Jinghong, Wei Qi, McCowen Karen, Xiong Wei, Liu Jiao, Jiang Wenlijun, Thomas Robert, Hepokoski Mark, He Ming, Shyy John, Malhotra Atul, Xiong Nian
University of California, San Diego.
Wuhan Red Cross Hospital.
Res Sq. 2021 Mar 26:rs.3.rs-287308. doi: 10.21203/rs.3.rs-287308/v1.
Type 2 diabetes mellitus (T2DM) is a strong risk factor for complications of coronavirus disease 2019 (COVID-19). The effect of T2DM medications on COVID-19 outcomes remains unclear. In a retrospective analysis of a cohort of 131 patients with T2DM hospitalized for COVID-19 in Wuhan, we have previously found that metformin use prior to hospitalization is associated with reduced mortality. Here we continue to investigate the effects of inpatient use of T2DM medications, including metformin, acarbose, insulin, and sulfonylureas, on the mortality of COVID-19 patients with T2DM during hospitalization. We found that patients using metformin and acarbose, alone or both together, after admission were significantly more likely to survive than those who did not use either metformin or acarbose. Thus, our analyses suggest that inpatient use of metformin and acarbose together or alone during hospitalization should be studied in randomized trials.
2型糖尿病（T2DM）是2019冠状病毒病（COVID-19）并发症的一个重要危险因素。T2DM药物对COVID-19结局的影响尚不清楚。在对武汉131例因COVID-19住院的T2DM患者队列进行的回顾性分析中，我们之前发现住院前使用二甲双胍与死亡率降低有关。在此，我们继续研究住院期间使用T2DM药物（包括二甲双胍、阿卡波糖、胰岛素和磺脲类药物）对T2DM合并COVID-19患者住院期间死亡率的影响。我们发现，入院后单独或联合使用二甲双胍和阿卡波糖的患者比未使用二甲双胍或阿卡波糖的患者存活的可能性显著更高。因此，我们的分析表明，应在随机试验中研究住院期间单独或联合使用二甲双胍和阿卡波糖的情况。
